{"protocolSection": {"identificationModule": {"nctId": "NCT02917031", "orgStudyIdInfo": {"id": "D1680C00016"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure", "officialTitle": "A 24-Week, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Effects of Saxagliptin and Sitagliptin in Patients With Type 2 Diabetes Mellitus and Heart Failure", "acronym": "MEASURE-HF"}, "statusModule": {"statusVerifiedDate": "2021-10", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2017-01-10", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2019-08-23", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-08-23", "type": "ACTUAL"}, "studyFirstSubmitDate": "2016-09-09", "studyFirstSubmitQcDate": "2016-09-26", "studyFirstPostDateStruct": {"date": "2016-09-28", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2021-05-25", "resultsFirstSubmitQcDate": "2021-05-25", "resultsFirstPostDateStruct": {"date": "2021-06-18", "type": "ACTUAL"}, "dispFirstSubmitDate": "2020-04-28", "dispFirstSubmitQcDate": "2020-04-28", "dispFirstPostDateStruct": {"date": "2020-05-04", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-11-05", "lastUpdatePostDateStruct": {"date": "2021-11-08", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "This is a 24 week, multicenter, randomized, double-blind, parallel group, placebo-controlled study to investigate the effects of saxagliptin and sitagliptin on cardiac dimensions and function in patients with type 2 diabetes (T2DM) mellitus and heart failure (HF)."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus", "Heart Failure"], "keywords": ["Type 2 Diabetes Mellitus", "Heart Failure", "Saxagliptin", "Sitagliptin"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 348, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Saxagliptin", "type": "ACTIVE_COMPARATOR", "description": "one tablet of saxagliptin 5 mg or 2.5 mg + one placebo capsule matching sitagliptin", "interventionNames": ["Drug: Saxagliptin", "Drug: Placebo to match sitagliptin"]}, {"label": "Sitagliptin", "type": "ACTIVE_COMPARATOR", "description": "one capsule of sitagliptin 100 mg or 50 mg + one placebo tablet matching saxagliptin", "interventionNames": ["Drug: Sitagliptin", "Drug: Placebo to match saxagliptin"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "one placebo tablet matching saxagliptin + one placebo capsule matching sitagliptin", "interventionNames": ["Drug: Placebo to match saxagliptin", "Drug: Placebo to match sitagliptin"]}], "interventions": [{"type": "DRUG", "name": "Saxagliptin", "description": "5 mg or 2.5 mg, plain, yellow, biconvex, round, film-coated tablet", "armGroupLabels": ["Saxagliptin"], "otherNames": ["Onglyza TM"]}, {"type": "DRUG", "name": "Sitagliptin", "description": "50 mg or 100 mg, gray capsule", "armGroupLabels": ["Sitagliptin"], "otherNames": ["Januvia\u00ae"]}, {"type": "DRUG", "name": "Placebo to match saxagliptin", "description": "2.5 mg or 5 mg, plain, yellow, biconvex, round, film-coated tablet", "armGroupLabels": ["Placebo", "Sitagliptin"]}, {"type": "DRUG", "name": "Placebo to match sitagliptin", "description": "50 mg or 100 mg, gray capsule", "armGroupLabels": ["Placebo", "Saxagliptin"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Left Ventricular End Diastolic Volume (LVEDV) Index Measured by Magnetic Resonance Imaging (MRI) at 24 Weeks", "description": "MRI was performed to evaluate LVEDV at baseline and Visit 10 (Week 24). Evaluated to exclude an increase in left ventricular end diastolic volume (LVEDV) index of greater than 10% of the overall baseline value (noninferiority margin) in patients with T2DM and HF treated with saxagliptin for 24 weeks, compared to placebo. Baseline is last assessment on or before the date of first dose.", "timeFrame": "Baseline to 24 weeks"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Left Ventricular End Systolic Volume (LVESV) Index, Measured by MRI at 24 Weeks.", "description": "Evaluation of the effects of saxagliptin compared to placebo on left ventricular end systolic volume (LVESV) index, after 24 weeks in patients with T2DM and HF.", "timeFrame": "Baseline to week 24"}, {"measure": "Change From Baseline in Left Ventricular Ejection Fraction (LVEF) Measured by MRI at 24 Weeks.", "description": "Evaluation the effects of saxagliptin compared to placebo on left ventricular end systolic volume (LVESV) index, left ventricular ejection fraction (LVEF), and left ventricular mass (LVM) after 24 weeks in patients with T2DM and HF.", "timeFrame": "Baseline to week 24"}, {"measure": "Change From Baseline in Left Ventricular Mass (LVM) Measured by MRI at 24 Weeks.", "description": "Evaluation of the effects of saxagliptin compared to placebo on left ventricular mass (LVM) after 24 weeks in patients with T2DM and HF.", "timeFrame": "At 24 week"}, {"measure": "Change From Baseline in NT-proBNP After 24 Weeks of Treatment", "description": "Evaluation of the effects of saxagliptin compared to placebo on N-terminal prohormone of brain natriuretic peptide (NT-proBNP) after 24 weeks of treatment.", "timeFrame": "Baseline to Week 28 (End of Study visit [EoS])"}, {"measure": "Number of Participants With Adverse Events", "description": "Assessment of safety and tolerability of saxagliptin and sitagliptin treatment in patients with T2DM and HF", "timeFrame": "From screening (Days -28 to -1) until Week 28 (follow-up visit)"}]}, "eligibilityModule": {"eligibilityCriteria": "INCLUSION CRITERIA:\n\n1. Provision of informed consent prior to any study specific procedure (Pre-screening ICF and Informed Consent collected at screening)\n2. Male or female, aged \u226518 years at the time of consent\n3. Documented, controlled T2DM, as defined by:\n\n   * Diagnosis of Type 2 DM based on current ADA guidelines (Appendix C) Treatment with stable doses of antidiabetic medications that have not increased or decreased for \u22658 weeks before screening\n   * For patients taking insulin, the investigator must query the patient at prescreening or screening regarding his/her usual total daily insulin dose (all types combined) during the previous 8 weeks. Insulin dosages during pre-screening and screening should not vary by more than \u00b120% on more than two occasions\n   * Dosage reductions of insulin and sulfonylurea agents may be considered at randomization to minimize the possibility of hypoglycemia\n\n     * Any reductions in the dosage of insulin and sulfonylurea agents will be at the discretion of the investigator\n     * For patients treated with insulin, consider a reduction in dose of 20% at randomization\n     * For patients receiving sulfonylurea agents, consider a reduction in dose of 50% or discontinue if on a dosage that is considered low at randomization\n4. HFrEF demonstrated by all 3 of the following criteria:\n\n   * History of HF and LVEF \u226445% within the last 6 months (echocardiogram, MRI, left ventriculography, or other accepted methodology). Patients without a recent assessment of LV function will undergo a local echocardiogram at the time of screening to determine ejection fraction\n   * Elevated NT-proBNP (\\>300 pg/mL) during screening\n   * Patients should receive background standard of care for HFrEF and be treated according to locally recognized guidelines as appropriate. Guideline-recommended medications should be used at recommended doses unless contraindicated or not tolerated. Therapy should have been individually optimized and stable for \\>or = 4 weeks (this does not apply to diuretics-see NB below) before screening visit and include (unless contraindicated or not tolerated):\n   * an ACE inhibitor, or ARB, or sacubitril/valsartan\n   * and\n   * a beta-blocker\n   * and\n   * if considered appropriate by the patient's treating physician; a mineralocorticoid receptor antagonist (MRA)\n   * NB: Most patients with heart failure require treatment with a diuretic to control sodium and water retention leading to volume overload. It is recognized that diuretic dosing may be titrated to symptoms, signs, weight, and other information and may thus vary. Each patient should, however, be treated with a diuretic regimen aimed at achieving optimal fluid/volume status for that individual\n5. Stable HF, with no evidence of volume overload (no rales, jugular venous distention, peripheral edema) at screening\n6. Women of childbearing potential (WOCBP):\n\n   * Must be using appropriate birth control to avoid pregnancy throughout the study and for up to 4 weeks after the last dose of investigational product\n   * Must have a negative serum or urine pregnancy test within 72 hours prior to the start of investigational product\n   * Must not be breastfeeding.\n\nEXCLUSION CRITERIA:\n\n1. MRI contraindications: all implanted defibrillators; implanted pacemakers and other devices/implants that in the judgment of the investigator preclude an MRI evaluation\n2. Patients with atrial fibrillation/flutter, or any rhythm that would impact on MRI imaging quality would be excluded. Patients with a prior history of atrial fibrillation or paroxysmal atrial fibrillation may be eligible for entry into the study based on the investigator's judgment related to the frequency of AF events and the patient's overall condition\n3. Body mass index \\>45 kg/m2 or any condition, including, but not limited to known claustrophobia, that may preclude the ability to perform an MRI scan of acceptable quality, or unwillingness to undergo MRI imaging\n4. Receiving incretin therapy (DPP4 inhibitors, GLP-1 mimetics), or having received incretin therapy within the previous 8 weeks of randomization\n5. Receiving therapy with a TZD or having received TZD therapy within the previous 8 weeks of randomization\n6. Type 1 diabetes mellitus\n7. History of unstable or rapidly progressing renal disease\n8. A central lab eGFR value \\<30 mL/min/1.73 m2 on pre-screening or screening\n9. New York Heart Association (NYHA) Class IV HF\n10. Myocardial infarction, stroke, transient ischemic attack, or coronary revascularization (percutaneous coronary intervention \\[PCI\\] or coronary artery bypass graft \\[CABG\\]) within the past 3 months of screening\n11. Inoperable aortic or mitral valvular heart disease. Recent (within 3 months) or planned valvular heart procedure\n12. Heart failure secondary to restrictive cardiomyopathy, active myocarditis, constrictive pericarditis, and hypertrophic obstructive cardiomyopathy\n13. Previous cardiac transplantation or transplantation indicated or expected within 6 months of randomization\n14. Contraindications to saxagliptin therapy as outlined in the saxagliptin Investigator's Brochure, or to sitagliptin therapy as outlined in the sitagliptin prescribing information\n15. Current treatment with strong cytochrome P450 (CYP) 3A4/5 inhibitors\n16. Involvement in the planning and/or conduct of the study (applies to both AZ staff and/or staff at the study site)\n17. Previous enrollment which disqualifies patient from re-enrollment based on the rules in Section 4.1 of the protocol, or previous randomization in the study\n18. Participation in another clinical study with an investigational product during the last 30 days\n19. Patients either employed by or immediate relatives of the Sponsor\n20. Known human immunodeficiency virus (HIV) infection\n21. Severe hepatic disease, including chronic active hepatitis. Positive serologic evidence of current infectious liver disease, including patients who are known to be positive for hepatitis B viral antibody IgM, hepatitis B surface antigen, or hepatitis C virus antibody; or aspartate transaminase (AST) or alanine transaminase (ALT) \\>3X the upper limit of normal; or total bilirubin (TB) \\>2 mg/dL\n22. Active malignancy requiring treatment at the time of Visit 1(with the exception of successfully treated basal cell or treated squamous cell carcinoma).\n23. Pregnant, positive pregnancy test, planning to become pregnant during clinical trial or breast feeding\n24. History of any clinically significant disease or disorder which, in the opinion of the investigator, may put the patient at risk because of participation in the study, may influence the results, or may limit the patient's ability to participate in or complete the study\n25. Unable or unwilling to provide written informed consent", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "130 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Research Site", "city": "Torrance", "state": "California", "zip": "90502", "country": "United States", "geoPoint": {"lat": 33.83585, "lon": -118.34063}}, {"facility": "Research Site", "city": "Upland", "state": "California", "zip": "91786", "country": "United States", "geoPoint": {"lat": 34.09751, "lon": -117.64839}}, {"facility": "Research Site", "city": "Miami", "state": "Florida", "zip": "33133", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Research Site", "city": "Ormond Beach", "state": "Florida", "zip": "32174", "country": "United States", "geoPoint": {"lat": 29.28581, "lon": -81.05589}}, {"facility": "Research Site", "city": "Chicago", "state": "Illinois", "zip": "60610", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Research Site", "city": "Bronx", "state": "New York", "zip": "10455", "country": "United States", "geoPoint": {"lat": 40.84985, "lon": -73.86641}}, {"facility": "Research Site", "city": "Bronx", "state": "New York", "zip": "10459", "country": "United States", "geoPoint": {"lat": 40.84985, "lon": -73.86641}}, {"facility": "Research Site", "city": "Sayre", "state": "Pennsylvania", "zip": "18840", "country": "United States", "geoPoint": {"lat": 41.97896, "lon": -76.5155}}, {"facility": "Research Site", "city": "Spartanburg", "state": "South Carolina", "zip": "29302", "country": "United States", "geoPoint": {"lat": 34.94957, "lon": -81.93205}}, {"facility": "Research Site", "city": "Houston", "state": "Texas", "zip": "77089", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Research Site", "city": "Milwaukee", "state": "Wisconsin", "zip": "64111", "country": "United States", "geoPoint": {"lat": 43.0389, "lon": -87.90647}}, {"facility": "Research Site", "city": "Sofia", "zip": "1142", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"facility": "Research Site", "city": "Sofia", "zip": "1431", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"facility": "Research Site", "city": "Sofia", "zip": "1606", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"facility": "Research Site", "city": "Sofia", "zip": "1618", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"facility": "Research Site", "city": "Sofia", "zip": "1784", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"facility": "Research Site", "city": "Chicoutimi", "state": "Quebec", "zip": "G7H 7K9", "country": "Canada", "geoPoint": {"lat": 48.41963, "lon": -71.06369}}, {"facility": "Research Site", "city": "Santiago", "zip": "8207257", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Research Site", "city": "Santiago", "zip": "8360160", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Research Site", "city": "Santiago", "zip": "8380453", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Research Site", "city": "Santiago", "zip": "8910259", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Research Site", "city": "Talcahuano", "zip": "4270918", "country": "Chile", "geoPoint": {"lat": -36.72494, "lon": -73.11684}}, {"facility": "Research Site", "city": "Vi\u00f1a del Mar", "zip": "2520997", "country": "Chile", "geoPoint": {"lat": -33.02457, "lon": -71.55183}}, {"facility": "Research Site", "city": "Balatonf\u00fcred", "zip": "8230", "country": "Hungary", "geoPoint": {"lat": 46.96188, "lon": 17.87187}}, {"facility": "Research Site", "city": "Budapest", "zip": "1122", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Research Site", "city": "Budapest", "zip": "1134", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Research Site", "city": "Budapest", "zip": "1171", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Research Site", "city": "Debrecen", "zip": "4032", "country": "Hungary", "geoPoint": {"lat": 47.53333, "lon": 21.63333}}, {"facility": "Research Site", "city": "Hajd\u00faszoboszl\u00f3", "zip": "4200", "country": "Hungary", "geoPoint": {"lat": 47.45, "lon": 21.4}}, {"facility": "Research Site", "city": "Kecskem\u00e9t", "zip": "6000", "country": "Hungary", "geoPoint": {"lat": 46.90618, "lon": 19.69128}}, {"facility": "Research Site", "city": "Kisv\u00e1rda", "zip": "4600", "country": "Hungary", "geoPoint": {"lat": 48.21667, "lon": 22.08333}}, {"facility": "Research Site", "city": "Ny\u00edregyh\u00e1za", "zip": "4400", "country": "Hungary", "geoPoint": {"lat": 47.95539, "lon": 21.71671}}, {"facility": "Research Site", "city": "Orosh\u00e1za", "zip": "5900", "country": "Hungary", "geoPoint": {"lat": 46.56667, "lon": 20.66667}}, {"facility": "Research Site", "city": "P\u00e9cs", "zip": "7623", "country": "Hungary", "geoPoint": {"lat": 46.08333, "lon": 18.23333}}, {"facility": "Research Site", "city": "Sz\u00e9kesfeh\u00e9rv\u00e1r", "zip": "8000", "country": "Hungary", "geoPoint": {"lat": 47.18995, "lon": 18.41034}}, {"facility": "Research Site", "city": "Busan", "zip": "49241", "country": "Korea, Republic of", "geoPoint": {"lat": 35.10278, "lon": 129.04028}}, {"facility": "Research Site", "city": "Daejeon", "zip": "35015", "country": "Korea, Republic of", "geoPoint": {"lat": 36.32139, "lon": 127.41972}}, {"facility": "Research Site", "city": "Gwangju", "zip": "61469", "country": "Korea, Republic of", "geoPoint": {"lat": 35.15472, "lon": 126.91556}}, {"facility": "Research Site", "city": "Hwaseong-si", "zip": "18450", "country": "Korea, Republic of", "geoPoint": {"lat": 37.20682, "lon": 126.8169}}, {"facility": "Research Site", "city": "Seongnam-si", "zip": "13620", "country": "Korea, Republic of", "geoPoint": {"lat": 37.43861, "lon": 127.13778}}, {"facility": "Research Site", "city": "Seoul", "zip": "02841", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Seoul", "zip": "03080", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Seoul", "zip": "03722", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Wonju-si", "zip": "26426", "country": "Korea, Republic of"}, {"facility": "Research Site", "city": "Brasov", "zip": "500365", "country": "Romania", "geoPoint": {"lat": 45.64861, "lon": 25.60613}}, {"facility": "Research Site", "city": "Iasi", "zip": "700304", "country": "Romania", "geoPoint": {"lat": 47.16667, "lon": 27.6}}, {"facility": "Research Site", "city": "Iasi", "zip": "700515", "country": "Romania", "geoPoint": {"lat": 47.16667, "lon": 27.6}}, {"facility": "Research Site", "city": "Izhevsk", "zip": "426035", "country": "Russian Federation", "geoPoint": {"lat": 56.84976, "lon": 53.20448}}, {"facility": "Research Site", "city": "Kemerovo", "zip": "650002", "country": "Russian Federation", "geoPoint": {"lat": 55.33333, "lon": 86.08333}}, {"facility": "Research Site", "city": "Moscow", "zip": "109263", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Research Site", "city": "Moscow", "zip": "115516", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Research Site", "city": "Moscow", "zip": "121551", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Research Site", "city": "Nizhnii Novgorod", "zip": "603018", "country": "Russian Federation", "geoPoint": {"lat": 56.32867, "lon": 44.00205}}, {"facility": "Research Site", "city": "Novosibirsk", "zip": "630055", "country": "Russian Federation", "geoPoint": {"lat": 55.0415, "lon": 82.9346}}, {"facility": "Research Site", "city": "Novosibirsk", "zip": "630087", "country": "Russian Federation", "geoPoint": {"lat": 55.0415, "lon": 82.9346}}, {"facility": "Research Site", "city": "Novosibirsk", "zip": "630089", "country": "Russian Federation", "geoPoint": {"lat": 55.0415, "lon": 82.9346}}, {"facility": "Research Site", "city": "Saint-Petersburg", "zip": "194354", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Research Site", "city": "Saint-Petersburg", "zip": "199226", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Research Site", "city": "St Petersburg", "zip": "197341", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Research Site", "city": "Tomsk", "zip": "634012", "country": "Russian Federation", "geoPoint": {"lat": 56.49771, "lon": 84.97437}}, {"facility": "Research Site", "city": "Tomsk", "zip": "634050", "country": "Russian Federation", "geoPoint": {"lat": 56.49771, "lon": 84.97437}}, {"facility": "Research Site", "city": "Yaroslavl", "zip": "150062", "country": "Russian Federation", "geoPoint": {"lat": 57.62987, "lon": 39.87368}}, {"facility": "Research Site", "city": "Bangkoknoi", "zip": "10700", "country": "Thailand", "geoPoint": {"lat": 13.76266, "lon": 100.47798}}, {"facility": "Research Site", "city": "Bangkok", "zip": "10330", "country": "Thailand", "geoPoint": {"lat": 13.75398, "lon": 100.50144}}, {"facility": "Research Site", "city": "Bangkok", "zip": "10400", "country": "Thailand", "geoPoint": {"lat": 13.75398, "lon": 100.50144}}, {"facility": "Research Site", "city": "Chiang Mai", "zip": "50200", "country": "Thailand", "geoPoint": {"lat": 18.79038, "lon": 98.98468}}, {"facility": "Research Site", "city": "Khon Kaen", "zip": "40002", "country": "Thailand", "geoPoint": {"lat": 16.44671, "lon": 102.833}}, {"facility": "Research Site", "city": "Ivano-Frankivsk", "zip": "76005", "country": "Ukraine", "geoPoint": {"lat": 48.9215, "lon": 24.70972}}, {"facility": "Research Site", "city": "Ivano-Frankivsk", "zip": "76018", "country": "Ukraine", "geoPoint": {"lat": 48.9215, "lon": 24.70972}}, {"facility": "Research Site", "city": "Kyiv", "zip": "02091", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Research Site", "city": "Kyiv", "zip": "02660", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Research Site", "city": "Kyiv", "zip": "03680", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Research Site", "city": "Lviv", "zip": "79015", "country": "Ukraine", "geoPoint": {"lat": 49.83826, "lon": 24.02324}}, {"facility": "Research Site", "city": "Rivne", "zip": "33007", "country": "Ukraine", "geoPoint": {"lat": 50.62308, "lon": 26.22743}}]}, "referencesModule": {"references": [{"pmid": "34693515", "type": "DERIVED", "citation": "Kanie T, Mizuno A, Takaoka Y, Suzuki T, Yoneoka D, Nishikawa Y, Tam WWS, Morze J, Rynkiewicz A, Xin Y, Wu O, Providencia R, Kwong JS. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. Cochrane Database Syst Rev. 2021 Oct 25;10(10):CD013650. doi: 10.1002/14651858.CD013650.pub2."}], "seeAlsoLinks": [{"label": "redacted Protocol (CSP)", "url": "https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D1680C00016&amp;attachmentIdentifier=40bdcbbf-1c2f-46b3-84aa-09c81798d7ac&amp;fileName=redacted_Protocol_(CSP).pdf&amp;versionIdentifier="}, {"label": "Statistical Analysis Plan (SAP)", "url": "https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D1680C00016&amp;attachmentIdentifier=98837851-1b7e-4675-b9bc-ab19d428b539&amp;fileName=redacted_Statisitical_Analysis_Plan_(SAP).pdf&amp;versionIdentifier="}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participants with documented Ejection Fraction \u2264 45% and NTproBNP \\> 300 pg/mL had eligibility criteria assessed within 28 days of screening period. Informed consent was obtained prior to any study-related procedures or dosing of IP. 1 subject was excluded from the FAS as incorrectly randomized. This subject was terminated from the study on the day of randomization and no investigational product was dispensed.", "recruitmentDetails": "Participants who met all the inclusion and exclusion criteria were enrolled in 9 countries.", "groups": [{"id": "FG000", "title": "Saxagliptin", "description": "Participants with an eGFR \u226550 mL/min/1.73m\\^2 received one saxagliptin 5 mg tablet and one sitaglipitin placebo capsule administered orally once daily for a 24-week treatment period. Participants with an eGFR \u226530 to \\<50 mL/min/1.73m\\^2, the dose of saxagliptin was adjusted to one 2.5 mg tablet."}, {"id": "FG001", "title": "Sitagliptin", "description": "Participants with an eGFR \u226550 mL/min/1.73m\\^2 received one sitagliptin 100 mg capsule and one saxagliptin placebo tablet administered orally once daily for a 24-week treatment period. Participants with an eGFR \u226530 to \\<50 mL/min/1.73m\\^2, the dose of sitagliptin was adjusted to one 50 mg capsule."}, {"id": "FG002", "title": "Placebo", "description": "Participants recieved one saxagliptin placebo tablet and one sitagliptin placebo capsule administered orally once daily for a 24-week treatment period as a control."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "comment": "Participants who received treatment", "achievements": [{"groupId": "FG000", "numSubjects": "112"}, {"groupId": "FG001", "numSubjects": "115"}, {"groupId": "FG002", "numSubjects": "120"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "94"}, {"groupId": "FG001", "numSubjects": "102"}, {"groupId": "FG002", "numSubjects": "105"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "13"}, {"groupId": "FG002", "numSubjects": "15"}]}], "dropWithdraws": [{"type": "Reason not specified", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "6"}]}, {"type": "Development of study-specific withdrawal criteria", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "5"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "4"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Saxagliptin", "description": "Participants with an eGFR \u226550 mL/min/1.73m\\^2 received one saxagliptin 5 mg tablet and one sitaglipitin placebo capsule administered orally once daily for a 24-week treatment period. Participants with an eGFR \u226530 to \\<50 mL/min/1.73m\\^2, the dose of saxagliptin was adjusted to one 2.5 mg tablet."}, {"id": "BG001", "title": "Sitagliptin", "description": "Participants with an eGFR \u226550 mL/min/1.73m\\^2 received one sitagliptin 100 mg capsule and one saxagliptin placebo tablet administered orally once daily for a 24-week treatment period. Participants with an eGFR \u226530 to \\<50 mL/min/1.73m\\^2, the dose of sitagliptin was adjusted to one 50 mg capsule."}, {"id": "BG002", "title": "Placebo", "description": "Participants recieved one saxagliptin placebo tablet and one sitagliptin placebo capsule administered orally once daily for a 24-week treatment period as a control."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "112"}, {"groupId": "BG001", "value": "115"}, {"groupId": "BG002", "value": "120"}, {"groupId": "BG003", "value": "347"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "64.6", "spread": "7.96"}, {"groupId": "BG001", "value": "64.9", "spread": "9.85"}, {"groupId": "BG002", "value": "66.5", "spread": "7.84"}, {"groupId": "BG003", "value": "65.4", "spread": "8.61"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "35"}, {"groupId": "BG001", "value": "36"}, {"groupId": "BG002", "value": "37"}, {"groupId": "BG003", "value": "108"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "77"}, {"groupId": "BG001", "value": "79"}, {"groupId": "BG002", "value": "83"}, {"groupId": "BG003", "value": "239"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "17"}, {"groupId": "BG003", "value": "43"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "102"}, {"groupId": "BG001", "value": "99"}, {"groupId": "BG002", "value": "103"}, {"groupId": "BG003", "value": "304"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "15"}, {"groupId": "BG003", "value": "49"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "4"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "94"}, {"groupId": "BG001", "value": "98"}, {"groupId": "BG002", "value": "102"}, {"groupId": "BG003", "value": "294"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Left Ventricular End Diastolic Volume (LVEDV) Index Measured by Magnetic Resonance Imaging (MRI) at 24 Weeks", "description": "MRI was performed to evaluate LVEDV at baseline and Visit 10 (Week 24). Evaluated to exclude an increase in left ventricular end diastolic volume (LVEDV) index of greater than 10% of the overall baseline value (noninferiority margin) in patients with T2DM and HF treated with saxagliptin for 24 weeks, compared to placebo. Baseline is last assessment on or before the date of first dose.", "populationDescription": "Full analysis set (FAS): All randomised patients who took at least one dose of the study medication. Here, overall number of participants analyzed presents only those participants who were analyzed for this particular outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mL/m^2", "timeFrame": "Baseline to 24 weeks", "groups": [{"id": "OG000", "title": "Saxagliptin", "description": "Participants with an eGFR \u226550 mL/min/1.73m\\^2 received one saxagliptin 5 mg tablet and one sitaglipitin placebo capsule administered orally once daily for a 24-week treatment period. Participants with an eGFR \u226530 to \\<50 mL/min/1.73m\\^2, the dose of saxagliptin was adjusted to one 2.5 mg tablet."}, {"id": "OG001", "title": "Placebo", "description": "Participants recieved one saxagliptin placebo tablet and one sitagliptin placebo capsule administered orally once daily for a 24-week treatment period as a control."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "96"}, {"groupId": "OG001", "value": "106"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-3.395", "spread": "15.3412"}, {"groupId": "OG001", "value": "-0.716", "spread": "18.1178"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline, saxagliptin versus placebo.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.252", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-2.595", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-7.040", "ciUpperLimit": "1.850"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Left Ventricular End Systolic Volume (LVESV) Index, Measured by MRI at 24 Weeks.", "description": "Evaluation of the effects of saxagliptin compared to placebo on left ventricular end systolic volume (LVESV) index, after 24 weeks in patients with T2DM and HF.", "populationDescription": "FAS: All randomised patients who took at least one dose of the study medication. Here, overall number of participants analysed presents only those participants who were analyzed for this particular outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mL/m2", "timeFrame": "Baseline to week 24", "groups": [{"id": "OG000", "title": "Saxagliptin", "description": "Participants with an eGFR \u226550 mL/min/1.73m\\^2 received one saxagliptin 5 mg tablet and one sitaglipitin placebo capsule administered orally once daily for a 24-week treatment period. Participants with an eGFR \u226530 to \\<50 mL/min/1.73m\\^2, the dose of saxagliptin was adjusted to one 2.5 mg tablet."}, {"id": "OG001", "title": "Placebo", "description": "Participants recieved one saxagliptin placebo tablet and one sitagliptin placebo capsule administered orally once daily for a 24-week treatment period as a control."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "96"}, {"groupId": "OG001", "value": "106"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.555", "spread": "12.4136"}, {"groupId": "OG001", "value": "-0.839", "spread": "17.2458"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Saxagliptin: Change from baseline", "nonInferiorityType": "SUPERIORITY", "pValue": "0.425", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.631", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.635", "ciUpperLimit": "2.373"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Left Ventricular Ejection Fraction (LVEF) Measured by MRI at 24 Weeks.", "description": "Evaluation the effects of saxagliptin compared to placebo on left ventricular end systolic volume (LVESV) index, left ventricular ejection fraction (LVEF), and left ventricular mass (LVM) after 24 weeks in patients with T2DM and HF.", "populationDescription": "Full analysis set (FAS): All randomised patients who took at least one dose of the study medication. Here, overall number of participants analysed presents only those participants who were analyzed for this particular outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage", "timeFrame": "Baseline to week 24", "groups": [{"id": "OG000", "title": "Saxagliptin", "description": "Participants with an eGFR \u226550 mL/min/1.73m\\^2 received one saxagliptin 5 mg tablet and one sitaglipitin placebo capsule administered orally once daily for a 24-week treatment period. Participants with an eGFR \u226530 to \\<50 mL/min/1.73m\\^2, the dose of saxagliptin was adjusted to one 2.5 mg tablet."}, {"id": "OG001", "title": "Placebo", "description": "Participants recieved one saxagliptin placebo tablet and one sitagliptin placebo capsule administered orally once daily for a 24-week treatment period as a control."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "96"}, {"groupId": "OG001", "value": "106"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.533", "spread": "7.1971"}, {"groupId": "OG001", "value": "0.298", "spread": "7.2843"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Saxagliptin vs Placebo:\n\nChange from baseline", "nonInferiorityType": "SUPERIORITY", "pValue": "0.925", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "0.100", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.996", "ciUpperLimit": "2.197"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Left Ventricular Mass (LVM) Measured by MRI at 24 Weeks.", "description": "Evaluation of the effects of saxagliptin compared to placebo on left ventricular mass (LVM) after 24 weeks in patients with T2DM and HF.", "populationDescription": "FAS: All randomised patients who took at least one dose of the study medication. Here, overall number of participants analysed presents only those participants who were analyzed for this particular outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Gram", "timeFrame": "At 24 week", "groups": [{"id": "OG000", "title": "Saxagliptin", "description": "Participants with an eGFR \u226550 mL/min/1.73m\\^2 received one saxagliptin 5 mg tablet and one sitaglipitin placebo capsule administered orally once daily for a 24-week treatment period. Participants with an eGFR \u226530 to \\<50 mL/min/1.73m\\^2, the dose of saxagliptin was adjusted to one 2.5 mg tablet."}, {"id": "OG001", "title": "Placebo", "description": "Participants recieved one saxagliptin placebo tablet and one sitagliptin placebo capsule administered orally once daily for a 24-week treatment period as a control."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "96"}, {"groupId": "OG001", "value": "106"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-4.211", "spread": "16.6003"}, {"groupId": "OG001", "value": "-0.758", "spread": "16.1763"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Saxagliptin vs placebo: Change from baseline", "nonInferiorityType": "SUPERIORITY", "pValue": "0.105", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-3.605", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-7.970", "ciUpperLimit": "0.760"}]}, {"type": "SECONDARY", "title": "Change From Baseline in NT-proBNP After 24 Weeks of Treatment", "description": "Evaluation of the effects of saxagliptin compared to placebo on N-terminal prohormone of brain natriuretic peptide (NT-proBNP) after 24 weeks of treatment.", "populationDescription": "FAS: All randomised patients who took at least one dose of the study medication. Here, overall number of participants analysed presents only those participants who were analyzed for this particular outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg/mL", "timeFrame": "Baseline to Week 28 (End of Study visit [EoS])", "groups": [{"id": "OG000", "title": "Saxagliptin", "description": "Participants with an eGFR \u226550 mL/min/1.73m\\^2 received one saxagliptin 5 mg tablet and one sitaglipitin placebo capsule administered orally once daily for a 24-week treatment period. Participants with an eGFR \u226530 to \\<50 mL/min/1.73m\\^2, the dose of saxagliptin was adjusted to one 2.5 mg tablet."}, {"id": "OG001", "title": "Placebo", "description": "Participants recieved one saxagliptin placebo tablet and one sitagliptin placebo capsule administered orally once daily for a 24-week treatment period as a control."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "93"}, {"groupId": "OG001", "value": "104"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-277.525", "spread": "1324.7471"}, {"groupId": "OG001", "value": "-61.895", "spread": "3415.9525"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Saxagliptin vs placebo: Change from baseline", "nonInferiorityType": "SUPERIORITY", "pValue": "0.796", "statisticalMethod": "ANCOVA", "paramType": "Ratio for relative change", "paramValue": "0.971", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.777", "ciUpperLimit": "1.214"}]}, {"type": "SECONDARY", "title": "Number of Participants With Adverse Events", "description": "Assessment of safety and tolerability of saxagliptin and sitagliptin treatment in patients with T2DM and HF", "populationDescription": "Safety analysis set (SAS): All randomised patients who took at least one dose of the study medication.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "From screening (Days -28 to -1) until Week 28 (follow-up visit)", "groups": [{"id": "OG000", "title": "Saxagliptin", "description": "Participants with an eGFR \u226550 mL/min/1.73m\\^2 received one saxagliptin 5 mg tablet and one sitaglipitin placebo capsule administered orally once daily for a 24-week treatment period. Participants with an eGFR \u226530 to \\<50 mL/min/1.73m\\^2, the dose of saxagliptin was adjusted to one 2.5 mg tablet."}, {"id": "OG001", "title": "Sitagliptin", "description": "Participants with an eGFR \u226550 mL/min/1.73m\\^2 received one sitagliptin 100 mg capsule and one saxagliptin placebo tablet administered orally once daily for a 24-week treatment period. Participants with an eGFR \u226530 to \\<50 mL/min/1.73m\\^2, the dose of sitagliptin was adjusted to one 50 mg capsule."}, {"id": "OG002", "title": "Placebo", "description": "Participants recieved one saxagliptin placebo tablet and one sitagliptin placebo capsule administered orally once daily for a 24-week treatment period as a control."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "112"}, {"groupId": "OG001", "value": "115"}, {"groupId": "OG002", "value": "120"}]}], "classes": [{"title": "Any AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "53"}, {"groupId": "OG001", "value": "51"}, {"groupId": "OG002", "value": "58"}]}]}, {"title": "Any severe AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "13"}, {"groupId": "OG002", "value": "14"}]}]}, {"title": "Any treatment related AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Any AE with outcome Death", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "4"}]}]}, {"title": "Any SAE", "categories": [{"measurements": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "19"}, {"groupId": "OG002", "value": "29"}]}]}, {"title": "Any treatment related SAE", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Any SAE leading to discontinuation of study treatment", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "4"}]}]}, {"title": "Any AE leading to discontinuation of study treatment", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "7"}]}]}, {"title": "Any Adverse event of special interest", "categories": [{"measurements": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "15"}, {"groupId": "OG002", "value": "16"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "timeFrame": "From screening (Days -28 to -1) until Week 28 (follow-up visit)", "description": "An AEs is the development of an undesirable medical condition or the deterioration of a preexisting medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product.", "eventGroups": [{"id": "EG000", "title": "Saxagliptin", "description": "Participants with an eGFR \u226550 mL/min/1.73m\\^2 received one saxagliptin 5 mg tablet and one sitaglipitin placebo capsule administered orally once daily for a 24-week treatment period. Participants with an eGFR \u226530 to \\<50 mL/min/1.73m\\^2, the dose of saxagliptin was adjusted to one 2.5 mg tablet.", "deathsNumAffected": 2, "deathsNumAtRisk": 112, "seriousNumAffected": 17, "seriousNumAtRisk": 112, "otherNumAffected": 8, "otherNumAtRisk": 112}, {"id": "EG001", "title": "Sitagliptin", "description": "Participants with an eGFR \u226550 mL/min/1.73m\\^2 received one sitagliptin 100 mg capsule and one saxagliptin placebo tablet administered orally once daily for a 24-week treatment period. Participants with an eGFR \u226530 to \\<50 mL/min/1.73m\\^2, the dose of sitagliptin was adjusted to one 50 mg capsule.", "deathsNumAffected": 3, "deathsNumAtRisk": 115, "seriousNumAffected": 19, "seriousNumAtRisk": 115, "otherNumAffected": 9, "otherNumAtRisk": 115}, {"id": "EG002", "title": "Placebo", "description": "Participants recieved one saxagliptin placebo tablet and one sitagliptin placebo capsule administered orally once daily for a 24-week treatment period as a control.", "deathsNumAffected": 4, "deathsNumAtRisk": 120, "seriousNumAffected": 29, "seriousNumAtRisk": 120, "otherNumAffected": 8, "otherNumAtRisk": 120}], "seriousEvents": [{"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 6, "numAtRisk": 120}]}, {"term": "Acute coronary syndrome", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 120}]}, {"term": "Angina unstable", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 120}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 120}]}, {"term": "Acute left ventricular failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 120}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 120}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 120}]}, {"term": "Bradycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 120}]}, {"term": "Cardiac failure acute", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 120}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 120}]}, {"term": "Supraventricular tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 120}]}, {"term": "Ventricular tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 120}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 120}]}, {"term": "Acute hepatitis B", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 120}]}, {"term": "Epididymitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 120}]}, {"term": "Laryngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 120}]}, {"term": "Sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 120}]}, {"term": "Ankle fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 120}]}, {"term": "Craniocerebral injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 120}]}, {"term": "Femur fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 120}]}, {"term": "Humerus fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 120}]}, {"term": "Lower limb fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 120}]}, {"term": "Pelvic fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 120}]}, {"term": "Spinal compression fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 120}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 120}]}, {"term": "Cerebral arteriosclerosis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 120}]}, {"term": "Cerebrovascular insufficiency", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 120}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 120}]}, {"term": "Ischaemic stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 120}]}, {"term": "Sudden cardiac death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 120}]}, {"term": "Cardiac death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 120}]}, {"term": "Death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 120}]}, {"term": "Diabetic foot", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 120}]}, {"term": "Skin ulcer", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 120}]}, {"term": "Acute kidney injury", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 120}]}, {"term": "Cystitis haemorrhagic", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 120}]}, {"term": "Renal colic", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 120}]}, {"term": "Bile duct stone", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 120}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 120}]}, {"term": "Diabetes mellitus inadequate control", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 120}]}, {"term": "Lactic acidosis", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 120}]}, {"term": "Hypertensive crisis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 120}]}, {"term": "Peripheral arterial occlusive disease", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 120}]}, {"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 120}]}, {"term": "Enterocolitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 120}]}, {"term": "Back disorder", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 120}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 120}]}, {"term": "Dyspnoea paroxysmal nocturnal", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 120}]}], "otherEvents": [{"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 112}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 4, "numAffected": 4, "numAtRisk": 120}]}, {"term": "Hyperglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 112}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 120}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 112}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 115}, {"groupId": "EG002", "numEvents": 4, "numAffected": 4, "numAtRisk": 120}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "AstraZeneca R&D", "organization": "AstraZeneca R&D", "email": "clinicaltrialtransparency@astrazeneca.com", "phone": "+46 766 346712"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2020-02-14", "uploadDate": "2021-11-05T06:09", "filename": "Prot_002.pdf", "size": 842515}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2020-10-14", "uploadDate": "2021-05-25T11:10", "filename": "SAP_001.pdf", "size": 737496}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Spain", "Taiwan"]}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}, {"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}, {"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC14", "name": "Heart and Blood Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068900", "term": "Sitagliptin Phosphate"}, {"id": "C000502994", "term": "Saxagliptin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Percutaneous", "relevance": "HIGH"}, {"id": "M228152", "name": "Saxagliptin", "asFound": "Manufacturer", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}